Pregnancy News and Research

Latest Pregnancy News and Research

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Bristol-Myers Squibb Company today announced two-year results of a study that supports use of ORENCIA® (abatacept) for methotrexate-naive patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

20 Oct 2009

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Elan Corporation, plc and Biogen Idec today announced multiple presentations at the American College of Gastroenterology (ACG) Annual Scientific Meeting, taking place October 23-28 in San Diego.

20 Oct 2009

Hunt in pairs to find a suitable date

Looking for success on the dating scene? MIT Sloan Assistant Professor Joshua M. Ackerman suggests it might be a good idea to bring a friend.

20 Oct 2009

Link between stress reduction and increase in pregancy rate established

Women who participated in a stress management program prior to or during their second IVF cycle had a 160 percent greater pregnancy rate than women who did not participate in a program, according to a study presented today at the American Society for Reproductive Medicine's 65th Annual Meeting.

20 Oct 2009

Substantial price reduction for 24 Chromosome Aneuploidy Screening

Gene Security Network, Inc. (GSN) today announced a substantial price reduction for its 24 Chromosome Aneuploidy Screening with Parental SupportTM. Effective immediately, pricing has been restructured to a single flat fee for testing of up to 24 embryos in an in vitro fertilization (IVF) cycle.

20 Oct 2009

UT student receives fellowship grant for pre-eclampsia research

Roxanna Irani, a M.D./Ph.D. student at The University of Texas Graduate School of Biomedical Sciences at Houston (GSBS), has received a $10,000 fellowship for her efforts to better understand a condition known as pre-eclampsia that threatens the lives of expectant women and their unborn children.

20 Oct 2009

New technique to treat metabolic disorders in babies while still in the womb

Researchers say a new development in cord blood transplants for inherited metabolic disorders may be curative for some babies who are treated while still in the womb.

20 Oct 2009

FDA approves new oral medication for renal cell carcinoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

20 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Mothers receiving HAART less likely to transmit HIV virus to their newborns through breastfeeding

Mothers receiving highly active antiretroviral therapy (HAART) to treat HIV-1 infection are less likely than untreated mothers to transmit the virus to their newborns through breastfeeding, according to a new study.

19 Oct 2009

Recent releases in global health

In light of a recent Guttmacher Institute report that indicated 70,000 women in developing countries die each year from unsafe abortion, a Lancet editorial outlines ways to reduce deaths, and says, "The current political climate is favourable, because the global-gag rule (the U.S. Government's policy on banning funding of foreign organisations linked to any type of abortion practice) is out of favour" (10/17).

19 Oct 2009

National Women's Law Center reports how insurance industry discriminates against women

The National Women's Law Center's (NWLC) groundbreaking report "Nowhere to Turn: How the Individual Health Insurance Market Fails Women," first released in September 2008, brought to light how the insurance industry discriminates against women.

15 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

Blocking folic acid action during early pregnancy leads to increased risk of abnormalities in growing baby

Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.

15 Oct 2009

Medications to reduce folic acid during pregnancy increase the risk of abnormalities in fetus

Pregnant women are advised to take vitamin supplements containing folic acid as part of their routine pre-natal care. Now, a new study warns that taking medications that reduce or block the actions of folic acid during the first trimester of pregnancy increase the risk that the growing baby will develop abnormalities.

14 Oct 2009

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Medtronic, Inc. today announced results of a study comparing the safety and effectiveness of INFUSE® Bone Graft to autogenous bone graft (bone harvested from the patient) when used in maxillary sinus floor augmentation.

14 Oct 2009

Children with low birth weight are at a higher risk of developing asthma later in life, says study

A new study from the medical university Karolinska Institutet in Stockholm shows that children born with low birth weight are at a higher risk of developing asthma later in life. The study, which is published in the journal Pediatrics, is based on data on the incidence of asthma in 10,918 twins from the Swedish Twin Registry.

14 Oct 2009

Pregnancy News and Research

Latest Pregnancy News and Research

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Bristol-Myers Squibb presents study data on ORENCIA for treating rheumatoid arthritis

Elan and Biogen Idec to present TYSABRI study data at ACG meeting

Hunt in pairs to find a suitable date

Link between stress reduction and increase in pregancy rate established

Substantial price reduction for 24 Chromosome Aneuploidy Screening

UT student receives fellowship grant for pre-eclampsia research

New technique to treat metabolic disorders in babies while still in the womb

FDA approves new oral medication for renal cell carcinoma

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Mothers receiving HAART less likely to transmit HIV virus to their newborns through breastfeeding

Recent releases in global health

National Women's Law Center reports how insurance industry discriminates against women

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Blocking folic acid action during early pregnancy leads to increased risk of abnormalities in growing baby

Medications to reduce folic acid during pregnancy increase the risk of abnormalities in fetus

Medtronic announces results of study comparing INFUSE Bone Graft to autogenous bone graft

Children with low birth weight are at a higher risk of developing asthma later in life, says study

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Pregnancy News and Research

Latest Pregnancy News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in